Blue Jet Healthcare FY26 Standalone Results Approved

Date: July 06, 2026

Income Statement Highlights (₹ in millions):

Revenue from Operations: ₹9,473.21 (FY25: ₹10,299.85) - Decrease of 8%
Other Income: ₹686.54 (FY25: ₹462.56) - Increase of 48.4%
Total Income: ₹10,159.75 (FY25: ₹10,762.41)
Cost of Materials Consumed: ₹3,881.33 (FY25: ₹5,402.45)
Employee Benefits Expense: ₹735.35 (FY25: ₹609.97)
Finance Costs: ₹62.39 (FY25: ₹0.98)
Depreciation and Amortization: ₹240.02 (FY25: ₹177.89)
Profit Before Tax: ₹3,325.12 (FY25: ₹4,060.99)
Tax Expense: ₹846.96 (FY25: ₹1,008.96)
Profit for the Year: ₹2,478.16 (FY25: ₹3,052.03)
Other Comprehensive Income/(Loss): (₹1.98) (FY25: ₹0.32)
Total Comprehensive Income: ₹2,476.18 (FY25: ₹3,052.35)
Earnings Per Share (Basic & Diluted): ₹14.29 (FY25: ₹17.59)

Balance Sheet Highlights (₹ in millions):

Total Assets: ₹16,411.58 (FY25: ₹14,175.31)
Property, Plant and Equipment: ₹2,529.10 (FY25: ₹2,596.42)
Capital Work in Progress: ₹1,013.76 (FY25: ₹888.84)
Right of Use Assets: ₹613.43 (FY25: ₹404.12)
Investments: ₹251.85 (Non-current) + ₹2,266.97 (Current) (FY25: ₹0 + ₹1,866.92)
Inventories: ₹1,873.89 (FY25: ₹2,639.24)
Trade Receivables: ₹3,390.46 (FY25: ₹3,495.33)
Cash and Cash Equivalents: ₹608.57 (FY25: ₹329.79)
Total Equity: ₹13,599.12 (FY25: ₹11,331.11)
Lease Liabilities: ₹421.84 (FY25: ₹199.86)
Trade Payables: ₹569.20 (FY25: ₹890.53)

Cash Flow Statement (₹ in millions):

Final dividend proposed for FY26: ₹1.20 per equity share (face value ₹2 each)
Dividend amount: ₹208.16 million
Subject to approval by shareholders at ensuing Annual General Meeting
Dividend for FY25: ₹1.20 per share (₹208.16 million) was declared and paid during the year

Property Title Issues:

Certain immovable properties (leasehold land and building) with gross carrying value of ₹2,066.82 million are not held in company's name
Properties are in name of Blue Circle Organics Private Limited (not promoters/directors/their relatives)
Title transfer is in process pursuant to scheme of amalgamation/merger

Tax Disputes:

Income tax disputes totaling ₹1,768.86 million (net of ₹165 million deposited) for AY 2020-21 to 2022-23 pending with Appellate Authority
Additional income tax dispute of ₹1.00 million for AY 2023-24

Contingent Liabilities:

₹646.44 million - Interest payable on disallowance of depreciation on goodwill for AY 2020-21 and brought forward unabsorbed depreciation
₹1.00 million - Income tax interest payable on disallowance of TDS & TCS
₹3.92 million - GST and Customs refund matters
₹1.87 million - Labour related matter (ongoing litigation by ex-employee for 50% back wages)

Capital Commitments:

Estimated amount of contracts remaining to be executed on capital account: ₹691.44 million (net of advances)

Segment Information:

Single reportable business segment: Manufacturing of Artificial Sweeteners, Contrast Media Intermediates, Pharma Intermediates, APIs
Geographic revenue: Norway (40.6%), France (35.6%), India (10.1%), Rest of world (13.7%)
Two major customers represent 40.64% and 30.45% of revenue respectively

Related Party Transactions:

Transactions with directors and entities controlled by directors disclosed in Note 36
Key management personnel compensation: ₹179.06 million for FY26

CSR Expenditure:

CSR expenditure of ₹44.50 million incurred during FY26 (2% of average net profits)
Focus areas: Education, Vocational Skills, Healthcare and Environmental Sustainability